Sign In
Buy FLXN
$25.10
-0.0069 (-0.0275%)
At Close: Jun 22, 2026
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
07:00am, Wednesday, 13'th Jan 2021
BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended December 3
Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
04:30pm, Thursday, 07'th Jan 2021
BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an
Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference
04:30pm, Monday, 07'th Dec 2020
BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 04'th Dec 2020
BURLINGTON, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stock units.
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 06'th Nov 2020
BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units.
Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
04:30pm, Thursday, 05'th Nov 2020
BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an
Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates
06:15pm, Wednesday, 04'th Nov 2020
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock
Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights
04:01pm, Wednesday, 04'th Nov 2020
BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020.
Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case
11:28am, Monday, 02'nd Nov 2020
Miller Value Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 13.01% for the quarter (net of fees), outperf
Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
04:30pm, Thursday, 29'th Oct 2020
BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. f
Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors
01:00pm, Wednesday, 19'th Aug 2020
BURLINGTON, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30pm, Friday, 07'th Aug 2020
BURLINGTON, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 25,315 restricted stock units.
How Does Flexion Therapeutics' (NASDAQ:FLXN) CEO Pay Compare With Company Performance?
05:22pm, Friday, 07'th Aug 2020
This article will reflect on the compensation paid to Mike Clayman who has served as CEO of Flexion Therapeutics, Inc...
Global Bone Cement Market Analysis to 2030 - COVID-19 Impact - ResearchAndMarkets.com
12:00am, Friday, 07'th Aug 2020
The
Analyzing Flexion Therapeutics's Unusual Options Activity
04:27pm, Thursday, 06'th Aug 2020
Shares of Flexion Therapeutics (NASDAQ: FLXN) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $12.23. * Sentiment: BULLISH * Option T
